Abstract
This monograph provides the background for new developments in gastroenterological pharmacology, particularly focussing on the two chronic inflammatory bowel diseases, ulcerative colitis (UC) and Crohn's disease (CD). These currently cause significant morbidity but largely elude satisfactory treatment. This is a challenge to drug designers and experimental physiologists alike. Their efforts will be much enhanced by further understanding the aspects of molecular pathogenesis and physiological dysregulation outlined in this valuable and timely survey.
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.